Affordable Access

deepdyve-link
Publisher Website

Targeting interleukin-6 for noninfectious uveitis.

Authors
  • Lin, Phoebe
Type
Published Article
Journal
Clinical ophthalmology (Auckland, N.Z.)
Publication Date
Jan 01, 2015
Volume
9
Pages
1697–1702
Identifiers
DOI: 10.2147/OPTH.S68595
PMID: 26392750
Source
Medline
Keywords
License
Unknown

Abstract

Interleukin-6 (IL-6) is a pleiotropic cytokine implicated in the pathogenesis of many immune-mediated disorders including several types of non-infectious uveitis. These uveitic conditions include Vogt-Koyanagi-Harada syndrome, uveitis associated with Behçet disease, and sarcoidosis. This review summarizes the role of IL-6 in immunity, highlighting its effect on Th17, Th1, and plasmablast differentiation. It reviews the downstream mediators activated in the process of IL-6 binding to its receptor complex. This review also summarizes the biologics targeting either IL-6 or the IL-6 receptor, including tocilizumab, sarilumab, sirukumab, olokizumab, clazakizumab, and siltuximab. The target, dosage, potential side effects, and potential uses of these biologics are summarized in this article based on the existing literature. In summary, anti-IL-6 therapy for non-infectious uveitis shows promise in terms of efficacy and side effect profile.

Report this publication

Statistics

Seen <100 times